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Research
Under the Clean Air Act (1990), the U.S. 
Environmental Protection Agency (EPA) is 
legislatively required to establish and enforce 
National Ambient Air Quality Standards 
(NAAQS) that have a margin of safety requi-
site to protect the health of the public (U.S. 
EPA 2009a). In establishing the margin of 
safety for ambient particulate matter (PM) 
< 2.5 µm (PM2.5) and < 10 µm (PM10) in 
aerodynamic diameter, the U.S. EPA and 
the Clean Air Scientific Advisory Committee 
recently examined both innate (e.g., genetic or 
developmental) and acquired (e.g., disease- or 
treatment-related) forms of susceptibility to its 
adverse health effects, including increased risk 
of cardiovascular disease (U.S. EPA 2009b). 
Antihyperlipidemics and estrogens are note-
worthy examples of the drug classes that were 
examined with treatment-related susceptibility 
to such effects in mind.
Several studies suggest that drugs in these 
classes modify the autonomic, atherosclerotic, 
and thrombotic effects of PM (Allen et al. 
2009; Baccarelli et al. 2008; Künzli et al. 2005; 
Schwartz et al. 2005). In addition, in a case–
control study set in northern Italy, Baccarelli 
et al. (2008) suggested that the association 
between PM and deep vein thrombosis is much 
weaker among women than among men, par-
ticularly among those women who were using 
hormone therapy. However, the existence of an 
interaction between PM and hormone therapy 
remains questionable because of the well-known 
potential for confounding associated with 
hormone therapy exposures in observational 
epidemiologic studies (Col and Pauker 2003; 
Hernán et al. 2008; Ray 2003). At the same 
time, the relative risk and severity of adverse 
PM effects experienced by both hormone ther-
apy users and nonusers remains important from 
the clinical, public health policy, and regulatory 
perspectives (Brook 2008a, 2008b), given the 
decreasing but otherwise pervasive use of hor-
mone therapy among postmenopausal U.S. 
women (Hersh et al. 2004; Tsai et al. 2010). 
More information about a potential association 
between PM and venous thromboembolism 
(VTE) in a randomized controlled trial of hor-
mone therapy is therefore needed. 
In this study, we examined the associa-
tion between PM and VTE and interaction 
between PM and hormone therapy in a ran-
domized,   placebo-controlled trial of estrogen 
(E) or estrogen plus progestin (E + P) among 
a large geographically and ethnically diverse 
population of postmenopausal women living 
in the United States.
Materials and Methods
Study population. The design of the Women’s 
Health Initiative (WHI) Hormone Therapy 
trials has been described previously (Hays et al. 
2003; Stefanick et al. 2003; National Institutes 
of Health 1998). Briefly, 27,347 post-
menopausal women 50–79 years of age in areas 
surrounding 40 clinical centers were enrolled 
in one of two randomized, double-blind trials 
between 1993 and 1998. In the E trial, which 
was open only to women without a uterus, 
participants were randomized to either oral 
conjugated equine estrogen (CEE) 0.25 mg/
day or placebo. In the E + P trial, women were 
randomized to CEE 0.625 mg/day plus oral 
medroxyprogesterone acetate 2.5 mg/day or 
placebo. Exclusion criteria differed slightly 
between the trials but were related to the pres-
ence of medical conditions associated with 
shortened survival or safety in both. Because of 
evidence of hormone therapy-related increases 
in VTE risk, women with a history of deep 
vein thrombosis or pulmonary embolism were 
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Ba c k g r o u n d: The putative effects of postmenopausal hormone therapy on the association between 
particulate matter (PM) air pollution and venous thromboembolism (VTE) have not been assessed 
in a randomized trial of hormone therapy, despite its widespread use among postmenopausal women.
oB j e c t i v e: In this study, we examined whether hormone therapy modifies the association of PM 
with VTE risk. 
Me t h o d s : Postmenopausal women 50–79 years of age (n = 26,450) who did not have a history 
of VTE and who were not taking anticoagulants were enrolled in the Women’s Health Initiative 
Hormone Therapy trials at 40 geographically diverse U.S. clinical centers. The women were ran-
domized to treatment with estrogen versus placebo (E trial) or to estrogen plus progestin versus pla-
cebo (E + P trial). We used age-stratified Cox proportional hazard models to examine the association 
between time to incident, centrally adjudicated VTE, and daily mean PM concentrations spatially 
interpolated at geocoded addresses of the participants and averaged over 1, 7, 30, and 365 days.
re s u l t s: During the follow-up period (mean, 7.7 years), 508 participants (2.0%) had VTEs at 
a rate of 2.6 events per 1,000 person-years. Unadjusted and covariate-adjusted VTE risk was not 
associated with concentrations of PM < 2.5 µm (PM2.5) or < 10 µm (PM10)] in aerodynamic diam-
eter and PM × active treatment interactions were not statistically significant (p > 0.05) regardless of 
PM averaging period, either before or after combining data from both trials [e.g., combined trial-
adjusted hazard ratios (95% confidence intervals) per 10 µg/m3 increase in annual mean PM2.5 and 
PM10, were 0.93 (0.54–1.60) and 1.05 (0.72–1.53), respectively]. Findings were insensitive to alter-
native exposure metrics, outcome definitions, time scales, analytic methods, and censoring dates.
co n c l u s i o n s: In contrast to prior research, our findings provide little evidence of an association 
between short-term or long-term PM exposure and VTE, or clinically important modification by 
randomized exposure to exogenous estrogens among postmenopausal women.
key w o r d s : air pollution, deep vein thrombosis, particulate matter, pulmonary embolism, 
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no longer enrolled in either trial as of July 
1997. The present study excluded 93 women 
who had no follow-up data, 312 women who 
reported a history of VTE at randomization, 
and 11 women who reported using antico-
agulants or vitamin K. We also excluded 481 
women with foreign addresses outside the 
United States, U.S. military, U.S. protector-
ate, Hawaiian, Alaskan, or missing addresses at 
the time of randomization or their event, all of 
which precluded estimation of PM exposures; 
a total of 26,450 women were included in the 
PM10 analyses. Analyses of PM2.5 excluded 
another 124 women who had a VTE event 
and 1,693 who dropped out of the trials 
before 1999, because PM2.5 data before 1999 
were unavailable (see “Environmental expo-
sures”). The recruitment, consent, and data 
collection processes of the study are overseen 
by institutional review boards at the Clinical 
Coordinating Center in the Fred Hutchinson 
Cancer Research Center and the 40 WHI clin-
ical centers. All participants provided written 
informed consent.
VTE event ascertainment. Study participants 
were followed up to assess clinical events every 
6 months and for an annual in-clinic visit (Curb 
et al. 2006; Cushman et al. 2004). All hospi-
tal records associated with possible VTE events 
were locally reviewed by trained physician adju-
dicators who were masked to treatment assign-
ment and then centrally adjudicated. A VTE 
event was defined as a centrally adjudicated deep 
vein thrombosis or pulmonary embolism that 
occurred between the date of randomization 
and 31 December 2004 (Curb et al. 2006); our 
primary outcome was the calendar date of the 
first VTE event postrandomization. Agreement 
between local and central adjudication was 97% 
(Curb et al. 2006). A diagnosis of deep vein 
thrombosis required documentation of a treat-
ing physician’s diagnosis and positive results 
of Doppler or duplex ultrasonography, veno-
graphy, plethysmography, or isotope scanning. 
A pulmonary embolism required documenta-
tion of a physician’s diagnosis and by positive 
results from ventilation-perfusion lung scanning, 
pulmonary angiography, or computed tomogra-
phy or by documented signs and symptoms sug-
gestive of pulmonary embolism in the presence 
of a documented deep vein thrombosis event. 
Both procedure-related (defined as events that 
occurred within 60 days after an invasive pro-
cedure) and nonprocedure-related events were 
included in the definition of VTE events for this 
study (Curb et al. 2006; Cushman et al. 2004).
Environmental exposures. We used data on 
the ambient concentrations of PM recorded 
at all U.S. EPA Air Quality System monitors 
operating in the contiguous United States and 
national-scale, log-normal ordinary kriging to 
spatially interpolate daily mean PM concentra-
tions at each geocoded participant address dur-
ing the study period (Liao et al. 2006; Whitsel 
et al. 2006). Women were assigned time-
varying PM measures for all calendar dates on 
which a VTE event occurred. Monitor data 
were available for PM10 and PM2.5 between 
1993–2004 and 1999–2004, respectively. We 
averaged spatially interpolated daily means 
over 1, 7, 30, and 365 days up to and includ-
ing the event date among women with VTE 
and among women who remained at risk at 
that date. Averaging times were left-truncated 
for the cohort because of the lack of PM data 
before randomization. Thus, the 7-day, 30-day, 
and 365-day average concentrations associated 
with events that occured less than 7, 30, and 
365 days after the randomization date were 
not calculable. We computed corresponding 
averaging times for daily mean temperature 
(degrees centigrade) using ambient temperature 
data recorded at all National Climatic Data 
Center meteorological stations within 50 km 
of each geocoded address of the participants.
Participant and neighborhood charac-
teristics. We examined the following partici-
pant characteristics as possible confounders 
of the association between PM and VTE: age 
(years); race/ethnicity (non-Hispanic black, 
non-Hispanic white, Hispanic, and other); 
education (four categories); history of coro-
nary heart disease, peripheral arterial disease, 
or stroke; any cancer excluding nonmelanoma-
tous skin cancers; femur or hip fracture; hyper-
cholesterolemia; use of aspirin or nonsteroidal 
anti-inflammatory drugs (NSAIDs); current 
smoking; body mass index (BMI; kilograms 
per meter squared); and physical activity (kilo-
calories per week per kilogram). Self-reported 
education, medication use over the previous 
2 weeks, medical history, and other character-
istics were determined at each visit by inter-
view and examination by trained and certified 
staff. Interim health events were identified via 
standardized medical record review and physi-
cian adjudication. Hypercholesterolemia was 
determined by history or use of antihyperlipi-
demics; peripheral arterial disease and coronary 
heart disease were determined by self-reported 
history at baseline or by medication use and 
incident disease during the follow-up period 
that was assessed through a review of medical 
records by trained adjudicators. We also exam-
ined a measure of census tract–level neighbor-
hood socioeconomic status (SES) because of 
its inverse association with other cardiovascular 
outcomes in this population (Bird et al. 2009). 
To construct neighborhood SES values we 
identified 12 theoretically relevant census-tract 
level variables from census data, and assessed 
their relationships using confirmatory factor 
analysis (Bird et al., 2009). We created an 
index from the six variables that loaded most 
highly on the factor that most represented SES: 
percentage of adults older than age 25 years 
with less than a high school education; per-
centage of unemployed men; percentage of 
households with income below the poverty 
line; percentage of households receiving public 
assistance; percentage of households with chil-
dren headed only by a female; and the median 
household income. We imputed missing val-
ues of baseline individual-level covariates using 
Imputation and Variance Estimation Software 
(IVEware; Raghunathan et al. 2002). All of the 
covariates listed above, except race/ethnicity 
and education, were time-varying covariates 
with values being updated on the calendar-
time scale.
Statistical analysis. Cox proportional hazard 
models analyzed time until VTE event, control-
ling for clustering within clinical centers. As 
detailed below, all models used calendar time 
as the time scale to minimize potential biases 
associated with comparing VTE risk at a given 
event date as a function of PM concentration. 
Thus, we considered the following model:
λ(t) =  
λ0j(t)exp[β1 × PM(t) + β2 × X(t) + β3 × X], 
  [1]
where λ0j(t) denotes the baseline hazard for 
the jth strata, t denotes calendar time, PM(t) 
denotes an individual’s PM value at time t, 
and X(t) and X denote the vectors containing 
the time-varying and time-invariant covariates 
used as controls in the model, respectively. We 
note that this model structure assumes that the 
effect of PM is acute, as only the value of PM 
at time t is allowed to impact risk of VTE for 
an individual (Haneuse et al. 2007; Krewski 
et al. 2000). Separate analyses were conducted 
for PM10 and PM2.5.
We used unadjusted models to examine the 
bivariate relationship between PM and VTE. 
Fully adjusted models controlled for trial mem-
bership (E vs. E + P), a within-trial indicator for 
treatment arm (active vs. placebo), time on study 
(days), continuous temperature (degrees centi-
grade), as well as the participant and neighbor-
hood characteristics that we defined previously. 
Within each model, the averaging times for PM 
and temperature were identical. We used SAS 
(version 9.1.3; SAS Institute Inc., Cary, NC) to 
fit all models and inspected weighted Schoenfeld 
residual plots to test the assumption of propor-
tional hazards for all covariates (Grambsch and 
Therneau 1994). Because of nonproportional-
ity, all models were stratified by birth cohort in 
5-year increments and by trial membership. All 
nondemographic variables were allowed to vary 
over the course of follow-up except for neigh-
borhood SES and physical activity, which were 
measured at baseline.
All analyses began by combining data from 
the E and E + P trials with an indicator for 
active treatment in either trial. Combined trial 
analyses were followed by separate analyses 
of the E and E + P trial data. In each analy-
sis, we first assessed the PM main effect using Shih et al.
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separate models for the 1-day, 7-day, 30-day, 
and 365-day average PM10 and PM2.5 concen-
trations and then the interactive effect between 
PM and treatment arm for each PM concen-
tration. We assessed the interaction between 
PM and treatment arm by examining the addi-
tion of a linear PM × hormone therapy treat-
ment arm interaction term and by comparing 
stratified models (E alone, E placebo, E + P, 
and E + P placebo) to assess nonlinear interac-
tion effects. PM-covariate interaction terms 
were also examined. Statistical significance was 
determined using a p-value of 0.05.
Time scale selection. The survival models 
presented above rely on a calendar time scale 
instead of time on study (time since random-
ization). When combined with time-varying 
PM exposure measures, the calendar time scale 
allows for more robust inferences concerning 
the association between PM and VTE. In par-
ticular, we normalized the events to the calendar 
time scale and computed time-varying measures 
of PM by time-averaging the PM data of each 
woman at risk of VTE for each of the actual 
VTE event dates. This method minimizes con-
founding by season and long-term trends com-
monly found in PM data analyses; provides 
a more meaningful summary of exposures of 
women who never experienced a VTE event 
(compared with simply allowing their PM expo-
sures at loss to follow-up to represent their PM 
exposures over the entire follow-up period); and 
more appropriately models the effects of PM on 
VTE as short term or acute in nature.
Results
Characteristics of the population. Of the 
26,450 women without a baseline history 
of VTE who met the inclusion criteria, 508 
(2.0%, or 2.6/1,000 person-years) had a VTE 
event: 202 (2.0%, or 2.6/1,000 person-years) 
in the E trial (mean follow-up, 7.5 years) and 
306 (1.9%, or 2.5/1,000 person-years) in 
the E + P trial (mean follow-up, 7.6 years). 
Women who experienced a VTE event dur-
ing the follow-up period tended to be older 
and non-Hispanic white, to have had a history 
of stroke or cancer, to have been taking aspi-
rin or an NSAID, and to have been randomly 
assigned to estrogen, with or without progestin, 
at baseline compared with women who did not 
have a VTE event during follow-up (Table 1). 
In Table 2 we present the mean PM concentra-
tions for each averaging period for the overall 
sample and by trial arm and VTE status. 
Associations between PM and VTE and 
interactions between PM and hormone ther-
apy treatment arm. Fully adjusted models that 
included baseline neighborhood SES data for 
neighborhoods were similar to those without 
neighborhood SES. Neighborhood SES was not 
significantly associated with VTE and therefore 
was not included in the fully adjusted models 
reported herein. In the combined trial analyses, 
unadjusted and adjusted overall hazard ratios 
(HRs) for VTE per 10-µg/m3 increase in PM2.5 
and in PM10 were close to and not significantly 
different from 1.0, regardless of the PM aver-
aging period (Table 3). HRs and 95% confi-
dence intervals (CIs) for VTE associated with 
Table 1. Baseline characteristics, overall and by VTE status.
VTE status
Characteristic Overall (n = 26,450) No VTE (n = 25,942) VTE (n = 508)
Age (years) 63.4 ± 7.2 63.4 ± 7.2 66.1 ± 6.6
Race/ethnicity
Non-Hispanic white 21,609 (81.7) 21,166 (81.6) 443 (87.2)
Non-Hispanic black 2,699 (10.2) 2,646 (10.2) 53 (10.4)
Hispanic 1,498 (5.7) 1,491 (5.7) 7 (1.4)
Other 644 (2.4) 639 (2.5) 5 (1.0)
Education
Some high school 2,130 (8.0) 2,085 (8.0) 45 (8.9)
High school graduate 5,454 (20.6) 5,348 (20.6) 106 (20.9)
Some college 10,733 (40.6) 10,531 (40.6) 202 (39.7)
≥ College degree 8,133 (30.8) 7,978 (30.8) 155 (30.5)
BMI (kg/m2) 29.1 ± 6.0 29.1 ± 6.0 31.2 ± 6.6
Coronary heart disease 494 (1.9) 484 (1.9) 10 (2.0)
Peripheral arterial disease 440 (1.7) 429 (1.7) 11 (2.2)
Stroke 294 (1.1) 285 (1.1) 9 (1.8)
Hypercholesterolemia 3,206 (12.1) 3,146 (12.1) 60 (11.8)
Cancer 840 (3.2) 817 (3.1) 23 (4.5)
Fracturea 211 (0.8) 206 (0.8) 5 (1.0)
Aspirin or NSAID use 10,150 (38.4) 9,906 (38.2) 244 (48.0)
Current smoking 2,735 (10.5) 2,693 (10.5) 50 (8.4)
Physical activity (kcal/kg/week) 10.0 ± 11.2 10.0 ± 11.2 8.7 ± 10.6
Randomization status
E 5,104 (19.3) 4,991 (19.2) 113 (22.2)
Placebo for E arm 5,228 (19.8) 5,139 (19.8) 89 (17.5)
E + P 8,255 (31.2) 8,064 (31.1) 191 (37.6)
Placebo for E + P arm 7,863 (29.7) 7,748 (29.9) 115 (22.6)
Daily temperature (°C) NA NA 13.0 ± 9.5
Season
January–March NA NA 177 (34.8)
April–June NA NA 124 (24.4)
July–September NA NA 150 (29.5)
October–December NA NA 57 (11.2)
Follow-up time (person-years) 198,048 195,898 2,150
Abbreviations: E, CEE, 0.625 mg/day; E + P, CEE, 0.625 mg/day plus medroxyprogesterone acetate, 0.25 mg/day; NA, not 
applicable for participants without event. Data are reported as n (%) or mean ± SD. Descriptive data include imputed 
baseline covariate data. 
aHip or femur. 
Table 2. Overall mean ± SD PM concentrations at baseline, by trial arm and by VTE status.
E trial E + P trial

















No VTE  
(n = 8,064) Averaging period (days)a
PM2.5 (µg/m3)
1 13.5 ± 7.7 13.5 ± 7.7 12.5 ± 7.2 13.5 ± 7.7 12.9 ± 7.0 13.5 ± 7.8 13.0 ± 7.3 13.5 ± 7.7 15.3 ± 9.3
7 13.5 ± 5.6 13.5 ± 5.6 12.5 ± 6.1 13.5 ± 5.6 13.7 ± 5.1 13.5 ± 5.6 13.7 ± 5.9 13.5 ± 5.6 13.6 ± 5.8
30 13.4 ± 4.4 13.4 ± 4.4 12.9 ± 4.1 13.4 ± 4.4 13.6 ± 4.1 13.4 ± 4.4 13.7 ± 4.3 13.4 ± 4.4 13.6 ± 4.8
365 13.4 ± 2.9 13.4 ± 2.9 13.1 ± 2.5 13.4 ± 2.9 13.2 ± 2.8 13.3 ± 2.8 13.7 ± 2.4 13.4 ± 2.8 13.4 ± 2.9
PM10 (µg/m3)
1 27.8 ± 12.3 27.9 ± 12.3 28.1 ± 10.9 27.9 ± 12.2 25.6 ± 9.6 27.7 ± 12.2 26.7 ± 10.3 27.7 ± 12.3 27.5 ± 12.0
7 27.1 ± 8.0 27.2 ± 8.0 26.0 ± 7.7 27.2 ± 8.0 26.4 ± 7.3 27.0 ± 7.9 26.8 ± 8.0 27.0 ± 8.0 26.5 ± 7.6
30 26.7 ± 6.1 26.8 ± 6.2 26.4 ± 6.2 26.9 ± 6.2 25.8 ± 5.3 26.7 ± 6.1 26.6 ± 6.2 26.7 ± 6.1 26.4 ± 6.0
365 26.7 ± 3.6 26.8 ± 3.7 26.7 ± 3.7 26.8 ± 3.7 26.7 ± 3.3 26.6 ± 3.6 26.8 ± 3.4 26.6 ± 3.6 26.7 ± 3.4
aPeriods (up to and ending on VTE event dates) over which averages were calculated. For those without VTE, averages are the corresponding averages over all at-risk days.Particulate matter and venous thromboembolism in women
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other model covariates in the combined trial 
analyses for PM10 are shown in Supplemental 
Material, Table A (doi:10.1289/ehp.1002256). 
Overall HRs in the trial-stratified analyses also 
were no different from the null, although they 
were somewhat higher among women in the 
E + P than in the E trial, except for the 30-day 
PM2.5 average (Table 4). The interaction terms 
between PM and randomized hormone therapy 
within each trial were not statistically signifi-
cant (p > 0.05), regardless of the PM-averaging 
period (Table 4). Moreover, p-values associated 
with other PM-covariate interactions exceeded 
0.1 (results not shown).
Sensitivity analyses. In addition to the pri-
mary analyses, we evaluated the sensitivity of 
findings to alternative exposure metrics, out-
come definitions, time scales, analytic methods, 
and trial-specific censoring dates. For example, 
we dichotomized 1-day and 365-day average 
PM concentrations at values representing cur-
rent U.S. EPA regulatory standards to evaluate 
potential threshold effects of exposure (U.S. 
EPA 1990). We also examined restricted dis-
tributed lag models (Pope and Schwartz 1996; 
Schwartz 2000) to evaluate PM effects as a cubic 
function of lagged daily concentrations within 
the 7-day averaging period. In addition to the 
primary VTE outcome, pulmonary embolism 
(without coincident deep vein thrombosis) and 
deep vein thrombosis (without coincident pul-
monary embolism) were also examined to eval-
uate their individual associations with PM and 
interactions between PM and hormone therapy. 
In other analyses, time on study was substituted 
for calendar time to evaluate whether use of the 
calendar time scale masked the true effect of 
PM (Mosteller and Tukey 1977). Moreover, 
although in the primary analyses the censoring 
date was 31 December 2004, the last date for 
which PM data were available, we examined 
whether associations using this date were dif-
ferent from those using the end dates of the 
two hormone therapy trials (8 July 2002 for 
the E trial; 1 March 2004 for the E + P trial) 
by restricting the follow-up time to events that 
occurred before those dates for each trial and 
rerunning all combined and trial-stratified 
models. Finally, we applied a case-crossover 
design using conditional logistic regression to 
analyze the odds of VTE in case compared with 
bidirectionally sampled case–referent exposure 
periods. These models controlled for short-term 
time trends in PM exposure and adjusted for 
average ambient temperature. All findings were 
robust to the adoption of the alternative expo-
sure metrics, outcome definitions, time scales, 
analytic methods, and trial-specific censoring 
dates (see “Materials and Methods”). In the 
adjusted analyses of the 365-day average PM2.5 
and PM10 on the time on study scale, for exam-
ple, the combined trial HRs were consistently 
null: 0.88 (95% CI, 0.52–1.47) and 1.10 (95% 
CI, 0.75–1.61), respectively, as were the trial-
stratified HRs. In the case-crossover analyses, 
odds ratios (95% CIs) for VTE per 10-µg/m3 
increase in average 1-day and 7-day PM2.5 were 
1.04 (0.85–1.28) and 0.93 (0.68–1.27), respec-
tively. The odds ratios for a 10-µg/m3 increase in 
1-day and 7-day PM10, were 1.03 (0.92–1.14) 
and 0.99 (0.81–1.20), respectively.
Discussion
In this large clinical trial population, we 
observed little evidence for an association of 
either PM10 or PM2.5 air pollution with risk 
of future VTE, over more than 7 years of fol-
low-up. Results were robustly null in analyses 
that examined daily, weekly, monthly, and 
annual average PM concentrations immedi-
ately preceding VTE events, adjusting for a 
comprehensive set of sociodemographic, clini-
cal, behavioral, and environmental covariates. 
There were no differences in findings compar-
ing women who were randomized to placebo 
or hormone therapy.
Although the current study did not find 
any consistent evidence of a direct association 
between VTE risk and short-term or long-
term PM2.5 or PM10 exposures in primary 
or sensitivity analyses, Baccarelli et al. (2008) 
found a strong, direct, and significant asso-
ciation between PM10 exposure and the risk of 
deep vein thrombosis in a case–control study 
conducted in the Lombardy region of Italy. 
This finding was internally consistent with the 
PM-related decreases in prothrombin time and 
in activated partial thromboplastin time that 
the study also observed among its controls. 
Moreover, other studies have suggested links 
between traffic or PM10 exposure, deep vein 
thrombosis (Baccarelli et al. 2009), pulmonary 
embolism (Colais et al. 2009), and VTE (Dales 
et al. 2010). The discrepant findings may be 
partly attributable to differences between study 
populations; for example, Baccarelli et al. 
(2008) included both men and women in their 
study. They observed lower VTE risk among 
women than among men, suggesting that there 
could be inherent or acquired differences in 
risk for VTE by sex that we were not able to 
observe in our sample of women. Women in 
the WHI Hormone Therapy trials were also 
older than those reported in Baccarelli et al. 
(2008), uniformly postmenopausal, mostly well 
educated, and likely to have had a substantial 
interest in their health. In addition, the asso-
ciation between PM10 and deep vein throm-
bosis described by Baccarelli et al. (2008) was 
not adjusted for history of cancer, which is a 
risk factor for deep vein thrombosis (Anderson 
and Spencer 2003; Goldhaber 1998; Lutsey 
et al. 2009; Severinsen et al. 2009). Finally, the 
chemical composition of ambient PM and its 
Table 4. HRs (95% CIs) for VTE per 10-µg/m3 increase in PM, by randomization status.a
E trial E + P trial
Averaging period (days) Total E trial Placebo E p-Valueb Total E + P trial Placebo E + P p-Valueb
PM2.5
1 0.97 (0.79–1.18) 0.94 (0.68–1.31) 0.98 (0.74–1.31) 0.86 1.10 (0.87–1.4) 0.97 (0.67–1.41) 1.18 (0.88–1.60) 0.42
7 0.98 (0.70–1.37) 0.78 (0.40 1.53) 1.13 (0.81–1.58) 0.32 1.01 (0.75–1.36) 1.12 (0.69–1.81) 0.94 (0.63–1.41) 0.60
30 1.07 (0.66–1.75) 0.76 (0.36–1.63) 1.31 (0.81–2.13) 0.14 0.98 (0.65–1.47) 1.02 (0.50–2.1) 0.95 (0.58–1.55) 0.86
365 0.67 (0.34–1.29) 0.54 (0.21–1.38) 0.77 (0.32–1.84) 0.58 1.21 (0.57–2.56) 2.07 (0.77–5.61) 0.81 (0.31–2.07) 0.12
PM10
1 0.95 (0.84–1.09) 1.06 (0.93–1.22) 0.87 (0.71–1.05) 0.06 1.01 (0.86–1.18) 0.97 (0.79–1.2) 1.02 (0.86–1.22) 0.67
7 0.90 (0.70–1.15) 0.86 (0.60–1.24) 0.93 (0.68–1.26) 0.74 0.92 (0.75–1.13) 0.95 (0.70–1.28) 0.90 (0.72–1.13) 0.78
30 0.89 (0.64–1.24) 1.02 (0.65–1.59) 0.82 (0.55–1.21) 0.41 0.96 (0.72–1.29) 1.00 (0.62–1.61) 0.94 (0.70–1.26) 0.79
365 0.83 (0.50–1.38) 1.04 (0.39–2.75) 0.71 (0.41–1.24) 0.52 1.23 (0.78–1.93) 1.29 (0.65–2.53) 1.20 (0.75–1.91) 0.83
aModels were stratified by birth cohort and trial arm and adjusted for race/ethnicity, education, BMI, coronary heart disease, peripheral arterial disease, stroke, cancer, fracture, 
aspirin or NSAID use, hypercholesterolemia, current smoking, physical activity, treatment duration (years), and temperature (degrees centigrade). bp-Value for the test of the 
PM × treatment interaction.









1 1.01 (0.88–1.16) 1.04 (0.89–1.22)
7 0.97 (0.78–1.20) 1.00 (0.78–1.28)
30 0.99 (0.76–1.29) 1.02 (0.73–1.43)
365 1.03 (0.66–1.62) 0.93 (0.54–1.60)
PM10
1 0.94 (0.86–1.03) 0.98 (0.88–1.10)
7 0.88 (0.76–1.02) 0.91 (0.77–1.08)
30 0.87 (0.71–1.05) 0.93 (0.74–1.16)
365 0.92 (0.65–1.29) 1.05 (0.72–1.53)
aModels were stratified by birth cohort (in 5-year incre-
ments) and trial arm. Adjusted models include race/
ethnicity, education, BMI, coronary heart disease, 
peripheral arterial disease, stroke, cancer, fracture, 
aspirin or NSAID use, hypercholesterolemia, current 
smoking, physical activity, hormone therapy treatment 
arm (active vs. placebo), treatment duration (years), and 
temperature (degrees centigrade).Shih et al.
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correlation with personal PM exposures may 
differ in northern Italy and in the United States 
(de Meij et al. 2009; Giugliano et al. 2005; 
Lonati et al. 2005).
Although PM-chemical component data 
are currently unavailable in the WHI, we were 
able to examine hormone therapy-related sus-
ceptibility to the putative effects of PM on 
VTE risk in the context of a randomized clini-
cal trial of estrogen with or without progestin. 
We did not find a consistent clinically or statis-
tically significant interactive effect of hormone 
therapy. Baccarelli et al. (2008) also examined 
the interactive effects of PM and exogenous 
estrogens on risk of deep vein thrombosis with 
or without pulmonary embolism; although 
no significant interactions were found at a 
Bonferroni-corrected alpha of 0.004, the strong 
and direct association between PM and deep 
vein thrombosis described by the researchers 
was much weaker among women than among 
men and among users of oral contraceptives or 
hormone therapy compared with women who 
were nonusers. These findings were counter-
intuitive, because the prothrombotic effects 
of PM (Liao et al. 2005) and estrogen (Curb 
et al. 2006; Cushman et al. 2004; Herrington 
et al. 2002; Sare et al. 2008) were expected to 
be synergistic (Brook 2008a). However, the 
case–control design of the study did not bene  fit 
from the equalization among treatment groups 
of measured, and most important, unmeas-
ured confounders that randomization typically 
affords. Studies that report protective effects 
of hormone therapy against coronary heart 
disease in observational settings conflict with 
more recent randomized trials of hormone 
therapy (Curb et al. 2006) and with reanalyses 
of those observational associations using meth-
ods less prone to bias (Col and Pauker 2003; 
Hernán et al. 2008; Ray 2003). Thus, the puta-
tive effects of hormone therapy and its interac-
tive effects with PM on VTE are particularly 
important to examine in the context of a ran-
domized trial, as has been done here, although 
neither PM exposure nor its inter  action with 
hormone therapy was randomized.
Prior findings from the WHI Observational 
Study are useful in placing the present findings 
from the WHI Hormone Therapy trials into 
proper perspective. Those findings included a 
24% (95% CI, 9–41) increase in the risk of 
a cardiovascular event, including death from 
coronary heart disease, or cerebrovascular dis-
ease, coronary revascularization, myocardial 
infarction, and stroke per 10-µg/m3 increase in 
the annual average PM2.5 concentration (Miller 
et al. 2007). The strength of that effect also 
varied in a striking and consistent way with 
several anthropometric measures. The gener-
ally null main and interactive effects described 
here contrast sharply with those of Miller et al. 
(2007) and suggest that observations of the 
WHI populations pertaining to the athero-
sclerotic and arterial effects of PM2.5 do not 
necessarily apply to its thromboembolic and 
venous effects, as has been intimated previously 
(Brook 2008a, 2008b).
The strengths of this study include the 
examination of a geographically and demo-
graphically diverse population of U.S. women 
who participated in a large randomized trial of 
postmenopausal hormone therapy, the rigor 
with which VTE outcomes were ascertained, 
and the analysis of PM10 as well as PM2.5, the 
particle size most relevant to regulatory efforts 
in the United States. Moreover, we distin-
guished between the effects of short-term (1-day 
or 7-day), medium-term (30-day), and long-
term (365-day) exposures to both PM2.5 and 
PM10 on both pulmonary embolism and deep 
vein thrombosis risk, using previously validated 
PM exposures measured across 1,270 counties 
in the United States (Liao et al. 2006).
Despite these strengths, we note several 
limitations. First, this study is based on post-
menopausal women 50–79 years of age who 
lived in the contiguous United States between 
1993 (or 1999 for those with PM2.5 measures) 
and 2004. Thus, inferences may not be gen-
eralizable to the U.S. population of adults 
including men and premenopausal women. 
Second, the distribution of PM concentrations 
in this study may not be fully representative 
of individual PM exposures across the United 
States. The temporally and spatially hetero-
geneous PM concentrations in this study are 
nonetheless associated with means, variances, 
and ranges comparable with those recorded by 
the U.S. EPA over the same time frame (U.S. 
EPA 2009c). Third, ambient PM concentra-
tions estimated in this study may not ade-
quately represent total PM exposures (Avery 
et al. 2010a, 2010b) as participants may have 
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been exposed to occupational or indoor PM 
with physicochemical properties and toxicities 
that differ from those of ambient PM (Monn 
and Becker 1999; Wainman et al. 2000). Even 
so, surveys of human-activity patterns sug-
gest that individuals spend a majority of their 
time at home (Klepeis et al. 2001), the loca-
tion where ambient PM concentrations in this 
study were estimated.
Conclusions
We consistently found little evidence of an 
association between VTE and PM2.5 or PM10 
concentrations in this study. Although innate 
participant characteristics remain unaccounted 
for in this study—including those that may 
influence genetic susceptibility to PM effects 
on VTE (Curb et al. 2006; Cushman et al. 
2004; Herrington et al. 2002; Martinelli et al. 
1999; Rosendaal et al. 1995)—genome-wide 
association studies (GWAS) are beginning to 
offer new opportunities to examine gene-PM 
interactions. Such studies hold promise for 
improved understanding of genetic and envi-
ronmental susceptibility to VTE.
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